The resulting hybrid gene produces BCR‐ABL1, a chimeric oncoprotein with constitutive tyrosine kinase activity that promotes CML by aberrantly phosphorylating target proteins. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.